Phase 2 clinical trials using JNJ-63733657 (a humanized anti-tau Ab) for cognitive dysfunction (NCT04619420) and UCB0107 (Bepranemab, a humanized IgG4 Ab against tau 235-250) for AD (NCT04867616) are currently being conducted. Here, MAPT is linked to Alzheimer disease.